Table 1 Clinical information of the patient cohort. TTP: time interval between the start of the re-irradiation treatment and the first progression
From: FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
|  | Patient cohort (n = 32) |
|---|---|
Age (years, median, range) | 52 (30–77) |
Sex | Â |
 Male | 17 (53.1%) |
 Female | 15 (46.9%) |
GBM | Â |
 Unifocal | 18 (56.3%) |
 Multifocal | 14 (43.7%) |
IDH-mutation | Â |
 Mutated | 10 (31.2%) |
 Wild-type | 14 (43.8%) |
 Unknown | 8 (25%) |
MGMT-status of recurrent tumor | Â |
 Methylated  Not methylated  Unknown | 7 (21.9%) 8 (25%) 17 (53.1%) |
Surgery of recurrent tumor before re-irradiation | Â |
 Yes  No | 25 (78.1%) 7 (21.9%) |
Time to progression (TTP) (days, median, range) | 91 (18–405) |
Overall survival (OS) (days, median, range) | 296.5 (18–1334) |